Norroy Successfully Shipped Mortenon M1 Automated Synthesis Module Overseas
Norroy Bioscience, a leading innovator in radiopharmaceutical development and automated synthesis module technology, has achieved a major milestone in its global expansion with the successful overseas shipment of its proprietary high-end nuclear medicine equipment Mortenon M1. This shipment marks an important step in Norroy’s business collaboration with Esente Healthcare.
This milestone follows the FDA’s approval for proceeding with the clinical development of 68Ga-NYM096, the company’s proprietary renal PET imaging agent, underscoring the strategic synergy between Norroy’s radiopharmaceutical pipeline and automated synthesis technology platform, as well as its commitment to advancing the global radiopharmaceutical ecosystem.
Mortenon M1 is scheduled for installation at ESENTE INNOVATION AND RESEARCH SOLUTIONS Pvt Ltd, the research arm of Esente Healthcare Pvt Ltd in India, where it will serve as a demonstration and application platform to support the customer’s engagement and radiopharmaceutical technology promotion across India. The module will also support ESENTE’s own GMP-compliant research and clinical production of conventional and novel radiotracers, delivering reproducible, high-quality radiopharmaceuticals while minimizing radiation exposure for operators.
Mortenon M1 is a next-generation automated synthesis module, featuring a fully integrated multi-functional cassette-based design. It combines the separation and purification of liquid- and solid-target generated radionuclides in a single workflow, enabling the efficient production of over 50 diagnostic and therapeutic radiopharmaceuticals, including small-molecule, peptide, and antibody-based radiopharmaceuticals. The plug-and-play cassette system leads to a rapid setup, consistent yields, and safe and convenient handling of radioactive materials, supporting both innovative research and routine GMP production.
To support global adoption and confidence in advanced synthesis technology, Norroy has pursued the international certification for its products, and Mortenon M1 has since obtained the EU CE and US FCC certifications. Peer reviewed publications documenting the applications of the technology platform in scientific and clinical settings have further demonstrated its superior performance and reliability.
The Mortenon M1 Platform has become an important part of our radiopharmaceutical production workflow. Its stable performance, integrated automation architecture, and user-friendly cassette-based operation support the reliable synthesis of a broad range of PET radiotracers for both clinical production and translational research.
The Mortenon M1 Platform supports a reliable and efficient radiopharmaceutical production workflow in our laboratory. The cassette-based design and flexible radiosynthesis configuration allow our team to handle both the routine tracer production and early-stage radiochemistry development using the same platform, while helping to optimize lab-use and support more cost-efficient day-to-day operations.
We particularly value the system’s operational flexibility and the responsiveness of the technical support team. The platform integrates well into our daily production activities while also supporting the evaluation and development of new radiotracers and radiolabeling experiments.
Beyond the equipment itself, the collaboration behind the platform has been highly valuable. Both the Norroy and Mortenon teams have demonstrated strong technical responsiveness and a clear understanding of the workflow requirements for radiopharmaceuticals production , supporting both our current production needs and future development plans.”
Norroy Bioscience continues to advance its worldwide strategy, expanding deployment of cutting edge automated nuclear medicine equipment and unmanned/robotic solutions for the radiopharmaceutical industry that reflect global best practices in radiopharmaceuticals manufacturing. With this initiative, Norroy aims to empower international research institutions and clinical facilities with its reliable, high performance technology and products that can adapt to the evolving tracer development and production needs—contributing to a more resilient and scalable global radiopharmaceutical ecosystem.
